Evaxion Biotech (EVAX) to implement ADS ratio change
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Evaxion announces plan to implement ADS ratio change
December 30, 2024 8:00 AM ESTCOPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares, DKK 1 nominal value (the ADS ratio), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the ADS ratio change). The ADS ratio change is expected to become effective on or about January 13, 2025, U.S. Eastern Time (the effective date).
... More